Australia - English - Department of Health (Therapeutic Goods Administration)

actavis australia pty ltd - acitretin -

Australia - English - Department of Health (Therapeutic Goods Administration)

advantage medical products consulting pty ltd - pitavastatin calcium, quantity: 4.18 mg (equivalent: pitavastatin, qty 4 mg) - tablet, film coated - excipient ingredients: aluminium magnesium silicate; lactose monohydrate; hypromellose; triethyl citrate; magnesium stearate; hyprolose; titanium dioxide; colloidal anhydrous silica - livalo is indicated as an adjunct to diet for the treatment of adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, when response to diet and other non-pharmacological measures is inadequate. prior to initiating therapy with livalo, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

advantage medical products consulting pty ltd - pitavastatin calcium, quantity: 2.09 mg (equivalent: pitavastatin, qty 2 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; triethyl citrate; aluminium magnesium silicate; magnesium stearate; lactose monohydrate; hypromellose; titanium dioxide; hyprolose - livalo is indicated as an adjunct to diet for the treatment of adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, when response to diet and other non-pharmacological measures is inadequate. prior to initiating therapy with livalo, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

advantage medical products consulting pty ltd - pitavastatin calcium, quantity: 1.045 mg (equivalent: pitavastatin, qty 1 mg) - tablet, film coated - excipient ingredients: hyprolose; titanium dioxide; triethyl citrate; hypromellose; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; aluminium magnesium silicate - livalo is indicated as an adjunct to diet for the treatment of adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, when response to diet and other non-pharmacological measures is inadequate. prior to initiating therapy with livalo, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

temps medical pty ltd - 61965 - medical device cleaning sponge - the medical soapy sponge is a novel product indicated for the daily hygiene of a patient and designed to achieve a complete, fast, simple and effective cleaning. they represent a breakthrough and play a vital role for caregivers and health professionals since they are responsible for providing daily hygiene to bedridden or mobility impaired patients. we are facing the perfect solution to prevent cross infections and reduce the costs that they entail. to date, traditional washing required warm water, soap, hand wipes, gauze, towels, lotion, etc. with the disposable soapy sponges, the carer will be able to do without all these and unify all the previous to a single product. the soapy sponges are dermatologically tested, with a ph neutral 5.5, valid for any type of skin even the most sensitive. hospitals in spain use our soapy sponge for the first bath of a newborn baby, as it has been proven to be soft and efficient in cleaning the skin. the use of soap sponge has numerous clinical advantages; decreases the re

Australia - English - Department of Health (Therapeutic Goods Administration)

evergrowth pty ltd - ginkgo biloba, quantity: 50 mg (equivalent: ginkgo biloba, qty 2.5 g; equivalent: ginkgolides and bilobalide, qty 3 mg; equivalent: ginkgo flavonglycosides, qty 12 mg) - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; povidone; macrogol 400; calcium hydrogen phosphate dihydrate; magnesium stearate; microcrystalline cellulose; crospovidone; carnauba wax - antioxidant/reduce free radicals formed in the body ; maintain/support healthy hearing ; maintain/support general health and wellbeing ; maintain/support healthy blood circulation ; maintain/support blood circulation/flow to the peripheral areas of the body (legs, hands and feet) ; maintain/support blood capillary health ; decrease/reduce/relieve aching/tired legs/leg heaviness associated with mild varicose veins ; maintain/support mental concentration/focus/clarity ; enhance/improve/promote/increase mental alertness/wakefulness ; maintain/support memory/mental recall

Australia - English - Department of Health (Therapeutic Goods Administration)

alphaxrt pty ltd - 38303 - radionuclide source, therapeutic, brachytherapy, manual, permanent implant - the seeds are placed in the tumor and the tumor then is exposed to gamma radiation from the seeds. this gamma radiation destroys the tumor cells by damaging the cell nucleus and other cell proteins and contents, preventing the cells from reproduction. the damaged cells cannot survive with the modified chromosomes and damaged proteins. the main intended use is the treatment of prostate cancer tumors. the i-125 advantage brachytherapy seeds are indicated for the treatment of selected localized tumours. the main intended use is the treatment of prostate cancer tumours.

Australia - English - Department of Health (Therapeutic Goods Administration)

acitretin -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - ivermectin - parenteral liquid/solution/suspension - ivermectin anthelmintic active 10.0 mg/ml - parasiticides

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - moxidectin; liquid hydrocarbon - topical solution/suspension - moxidectin anthelmintic active 5.0 g/l; liquid hydrocarbon solvent other 150.0 g/l - parasiticides